Tumor-Infiltrating Lymphocyte Therapy Shows Promise in Advanced Melanoma with Sustained Response Rates
核心洞察
A systematic review of seven studies demonstrates that tumor-infiltrating lymphocyte (TIL) therapy achieves objective response rates of 14-49% and overall survival ranging from 8-48 months in patients with advanced melanoma (搜索).
The FDA-approved lifileucel therapy showed a 31.4% objective response rate with median overall survival of 13.9 months and 5-year survival of 19.7% in heavily pretreated patients.
A case study reports successful TIL therapy in a patient with concurrent advanced melanoma (搜索) and chronic lymphocytic leukemia (搜索), achieving durable response with complete molecular clearance of circulating tumor DNA.
Advanced melanoma (搜索) patients who have exhausted standard immunotherapy options now have new hope with tumor-infiltrating lymphocyte (TIL) therapy, according to recent clinical evidence demonstrating sustained response rates and the potential for long-term remission. The therapy has shown particular promise following the 2024 FDA approval of lifileucel (Amtagvi), marking a breakthrough in adoptive cell therapy for cancer treatment.
Systematic Review Reveals Consistent Efficacy
A comprehensive systematic review analyzing seven clinical studies found that TIL therapy consistently produces objective response rates ranging from 14% to 49% across different patient populations with advanced melanoma (搜索). The studies, which included randomized controlled trials and phase II/III clinical trials, demonstrated overall survival outcomes spanning 8 to 48 months, with all studies showing TIL therapy's ability to achieve complete responses in up to 20% of patients.
The most significant finding came from the C-144-01 study of lifileucel, which enrolled 153 heavily pretreated patients with advanced melanoma (搜索). This pivotal trial demonstrated an objective response rate of 31.4%, with 5.9% achieving complete responses and 25.5% partial responses. The median duration of response reached 36.5 months, while overall survival was 13.9 months with a 5-year survival rate of 19.7%. Notably, 79% of patients showed tumor shrinkage.
Superior Performance Against Standard Care
Direct comparison studies revealed TIL therapy's superiority over existing treatments. In a randomized trial comparing TIL therapy to ipilimumab in patients with anti-PD-1 (搜索)-resistant advanced melanoma (搜索), TIL therapy achieved a median progression-free survival of 7.2 months compared to 3.1 months with ipilimumab. The objective response rate was 49% for TIL therapy versus 21% for ipilimumab, representing a significant improvement in treatment outcomes.
The Andersen study reported particularly encouraging results with a 42% overall response rate, including three complete responses and seven partial responses among 25 patients. The median overall survival reached 21.8 months, with researchers noting that patients receiving more infused tumor-reactive T cells experienced better tumor regression.
Treatment Characteristics and Safety Profile
TIL therapy involves a multi-step process beginning with lymphodepleting chemotherapy using cyclophosphamide and fludarabine, followed by infusion of ex vivo expanded autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 (IL-2). The treatment's safety profile reflects known toxicities associated with lymphodepletion and IL-2 administration, with adverse events being generally manageable without intensive care unit involvement.
Studies consistently showed that patients who received higher numbers of TILs demonstrated improved outcomes, particularly in those without prior anti-CTLA4 therapy. The Forget study found that median survival was highest at 24.6 months for patients with no prior CTLA4 treatment, compared to lower survival rates in previously treated patients.
Breakthrough Case in Complex Patient Population
A groundbreaking case study demonstrated TIL therapy's feasibility in a patient with concurrent advanced melanoma (搜索) and chronic lymphocytic leukemia (搜索) (CLL), a population historically excluded from clinical trials. The patient, who had stage 0 CLL and BRAF (搜索) D594N mutant melanoma, achieved a partial response by RECIST criteria at 6 weeks, with a continuous 65% decrease in target lesions at 12 months.
The treatment required careful management, including pre-treatment with obinutuzumab to achieve optimal lymphodepletion. Despite the complexity of managing dual malignancies, the patient experienced no new adverse events beyond those expected from standard TIL therapy. Circulating tumor DNA analysis showed complete molecular clearance within 4 months of treatment, maintained through 12-month follow-up.
Immunological Insights Drive Response
Analysis of the harvested tumor tissue revealed key factors contributing to treatment success. The tumor microenvironment was enriched with CD8 (搜索)+ T cells and demonstrated T-myeloid cell networks previously associated with TIL response. The final TIL product contained 69.5% CD8+ T cells, with 25.9% being CD39negCD69neg stem-like cells linked to long-term persistence and durable anti-tumor efficacy.
TCR sequencing demonstrated 60% overlap between infused TIL and peripheral blood cells at 9-month follow-up, indicating strong persistence of the therapeutic product. The polyclonal nature of the TIL product, with top 50 clones accounting for approximately one-third of total clones, suggested robust immune diversity.
Clinical Implementation and Future Directions
The evidence supports TIL therapy as an effective second-line treatment for advanced melanoma (搜索), particularly for patients who have failed checkpoint inhibitor therapy. Cost-effectiveness analyses have found TILs to be cost-saving compared to treatments like ipilimumab, supporting broader clinical implementation.
While the FDA has approved lifileucel for advanced melanoma (搜索), evaluations by regulatory bodies in other regions, including ongoing NICE assessments in the UK, highlight the need for continued evidence generation. Larger cohort studies, including the TILVANCE-301 phase 3 trial combining lifileucel with pembrolizumab, are expected to provide additional data supporting the therapy's clinical utility.
The treatment's success in complex patient populations, including those with concurrent hematologic malignancies, suggests potential for expanded applications. However, researchers emphasize that such cases require careful multidisciplinary evaluation and should be considered on an individual basis, particularly for patients with higher-stage CLL who may face increased treatment risks.